← Every company
Eli Lilly and Co Patents
What Eli Lilly and Co has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
LLY on carbonthat →Filings on file
67
Granted
0
Still pending
67
Filed under
2 names
67 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| MEDICATION DELIVERY DEVICE WITH NEEDLE CARRIERA61M 5/2429, A61M 5/3293, A61M 5/206, A61M 5/20, A61M 5/2033, A61M 5/281, A61M 5/31511, A61M 5/3202, A61M 5/3275, A61M 5/3276, A61M 5/348, A61M2005/2474, A61M2005/3206, A61M2005/3267, A61M2202/0007Filed as Eli Lilly and Company2026-06-15Jared Alden JUDSON | pending |
| OXYNTOMODULIN BINDING MOLECULES, AND USES THEREOFC07K 16/26, C07K2317/14, C07K2317/33, C07K2317/34, C07K2317/565, C07K2319/60, C12N 15/63, G01N 33/6893, G01N 33/74, G01N2800/042, G01N2800/50Filed as ELI LILLY AND COMPANY2026-06-11Robert John KONRAD | pending |
| COCRYSTALLINE FORMS OF FGFR3 INHIBITORSC07D 471/04, A61P 19/04, A61P 19/00, A61P 35/02, A61P 11/00, A61P 35/00, A61K 31/4545, C07B2200/13, C07C 65/05, C07D 213/82Filed as Eli Lilly and Company2026-06-09David Andrew COATES | pending |
| EXTENDED TIME ACTION ACYLATED INSULIN COMPOUNDSA61K 47/542, C07K 14/62, A61K 47/65, A61P 3/10, A61K 38/00, A61K 38/28Filed as Eli Lilly and Company2026-04-28Seamus Patrick BRENNAN | pending |
| METHODS AND APPARATUS FOR VISUAL-AWARE HIERARCHY-BASED OBJECT RECOGNITIONG06V 20/20, G16H 30/40, G16H 20/60, G06V 20/68, G06V 20/70, G06V 10/762, G06V 10/454, G06V 10/761, G06V 10/82, G06V 10/44, G06V 10/255, G06F 18/22, G06F 18/24317, G06F 18/2414, G06F 18/231, G01N 33/02Filed as Eli Lilly and Company2026-04-24Edward John DELP III | pending |
| Fc-ACYLATED POLYPEPTIDE CONJUGATESA61K 47/6811, A61K 47/68, A61K 47/542, A61K 47/6813, A61P 3/04, C07K 14/001, C07K 14/605, C07K2319/30Filed as ELI LILLY AND COMPANY2026-04-17Robert Andrew BROWN | pending |
| COMBINATION THERAPIES FOR THE TREATMENT OF CANCERFiled as ELI LILLY AND COMPANY2026-03-23NATHAN A. BROOKS | pending |
| METHODS OF USING RETATRUTIDEFiled as ELI LILLY AND COMPANY2026-03-20XIAOTIAN ZHANG | pending |
| DOSING ANTI-FOLATE RECEPTOR ALPHA ANTIBODY DRUG CONJUGATESFiled as ELI LILLY AND COMPANY2026-03-18EMIN AVSAR | pending |
| DOSING ANTI-FOLATE RECEPTOR ALPHA ANTIBODY DRUG CONJUGATESA61K 47/68037, A61K 47/6889, A61K 47/6849, A61P 35/00, A61K2039/505, C07K 16/22, C07K 16/28Filed as Eli Lilly and Company2026-03-18Emin AVSAR | pending |
| SUBSTITUTED FUSED PYRROLO[3,4-B]PYRIDINE COMPOUNDS AS AMYLIN RECEPTOR AGONISTS AND THEIR USE AS THERAPIESFiled as ELI LILLY AND COMPANY2026-03-10ANA MARIA CASTANO | pending |
| SUBSTITUTED 6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDINE COMPOUNDS AS AMYLIN RECEPTOR AGONISTS AND THEIR USE AS THERAPIESFiled as ELI LILLY AND COMPANY2026-03-10RENATO A. BAUER | pending |
| NOVEL THERAPEUTIC DELIVERY MOIETIES AND USES THEREOFFiled as ELI LILLY AND COMPANY2026-03-10KWAME FRIMPONG | pending |
| POLYMORPHS OF AN INTEGRIN Alpha5Beta1C07D 471/04, A61K 31/4375Filed as ELI LILLY AND COMPANY2026-03-09David Andrew COATES | pending |
| POLYMORPHS OF AN INTEGRIN ALPHA5BETA1Filed as ELI LILLY AND COMPANY2026-03-09DAVID ANDREW COATES | pending |
| COMPOUNDS SELECTIVE FOR THE AMY1 RECEPTORFiled as ELI LILLY AND COMPANY2026-03-09MILATA MARY ABRAHAM | pending |
| ANTI-IL-23 ANTIBODIES AND GIP/GLP-1 RECEPTOR AGONISTS FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASEFiled as ELI LILLY AND COMPANY2026-03-03TREVOR WARREN LISSOOS | pending |
| ANTI-IL-23 ANTIBODIES AND GIP/GLP-1 RECEPTOR AGONISTS FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITISFiled as ELI LILLY AND COMPANY2026-03-03TREVOR WARREN LISSOOS | pending |
| ACTRII RECEPTOR ANTIBODY FORMULATIONSFiled as ELI LILLY AND COMPANY2026-02-27ANDREW G. WERNER | pending |
| STRAIN GAUGE SENSORG01L 1/2287, B05D 1/005, B05D 1/32, B05D 3/0473, B05D 3/108, B05D 3/148, B05D 5/12, B05D2203/35, B05D2518/12, B05D2601/28, C08J 9/125, C08J 9/40, C08J2205/048, C08J2383/04, C08K 7/06, C08K2201/001Filed as Eli Lilly and Company2026-02-27Seokkyoon HONG | pending |
| CRYSTALLINE FORMS AND FORMULATIONS OF A KRAS INHIBITORC07D 519/00, A61P 35/00, A61K 9/0053, A61K 9/4858, A61K 9/4866, A61K 9/4891, A61K 31/517, A61K 31/519, A61K 45/06, C07D 275/06Filed as Eli Lilly and Company2026-02-27Robert William BONDI Jr. | pending |
| CRYSTALLINE FORMS AND FORMULATIONS OF A KRAS INHIBITORFiled as ELI LILLY AND COMPANY2026-02-27ROBERT WILLIAM BONDI JR. | pending |
| METHODS FOR THE PREPARATION OF LP(A) INHIBITOR COMPOUNDSFiled as ELI LILLY AND COMPANY2026-02-23MATTHEW JAMES GENZINK | pending |
| RNA STRUCTURES AND USES OF THE SAMEFiled as ELI LILLY AND COMPANY2026-02-23SAMANTHA MARA SARETT | pending |
| DOSE DETECTION AND DRUG IDENTIFICATION FOR A MEDICATION DELIVERY DEVICEA61M 5/31535, A61M 5/31568, A61M 5/0091, A61M 5/009, A61M 5/20, A61M 5/3155, A61M 5/31551, A61M2005/2006, A61M2005/3126, A61M2205/3306, A61M2205/3317, A61M2205/3561, A61M2205/3584, A61M2205/52, A61M2205/6054Filed as Eli Lilly and Company2026-02-18Roy Howard BYERLY | pending |
| SPEED OF MOVEMENT SYSTEM AND METHODFiled as Eli Lilly and Company2026-02-18Eric Todd ANTTONEN | pending |
| SYSTEMS AND METHODS FOR IGNITING PLASMA WITHIN TUBESH05H 1/246, H01J 37/32394, H05H2245/42, H05H2245/40, H05H 1/2431, B29C 59/005, B29C 59/142, B29C2059/145, B29K2023/0633Filed as Eli Lilly and Company2026-02-16Andrew Pennington MYERS | pending |
| POLYMORPHS OF AN INTEGRIN Alpha5Beta1Filed as ELI LILLY AND COMPANY2026-02-10David Andrew COATES | pending |
| TRANSFERRIN RECEPTOR BINDING PROTEINS AND USES THEREOFFiled as ELI LILLY AND COMPANY2026-01-23ALBERTO ALVARADO | pending |
| MEDICATION DELIVERY DEVICE WITH AUDIBLE FEEDBACK DURING INJECTIONFiled as ELI LILLY AND COMPANY2026-01-22WILLIAM GODWIN ATTERBURY | pending |
| MEDICATION DELIVERY DEVICE WITH SENSING SYSTEMA61M 5/31568, A61M 5/24, A61M 5/3155, A61M 5/31553, A61M 5/31593, A61M2005/3126, A61M2205/3584, A61M2205/52, A61M2205/6072Filed as Eli Lilly and Company2026-01-16Jay Mark FRIEDLANDER | pending |
| DOSING ANTI-FOLATE RECEPTOR ALPHA ANTIBODY DRUG CONJUGATESFiled as Eli Lilly and Company2026-01-15Emin AVSAR | pending |
| PROCESS FOR THE PREPARATION OF A GLP-1 RECEPTOR AGONISTFiled as ELI LILLY AND COMPANY2026-01-15MARK DAVID ARGENTINE | pending |
| PROCESSES FOR THE PREPARATION OF AN INTERMEDIATE FOR A GLP-1 RECEPTOR AGONISTFiled as ELI LILLY AND COMPANY2026-01-15NEIL JOHN KALLMAN | pending |
| DOSING, DOSING REGIMENS, CRYSTALLINE FORMS, AND DISPERSIONS OF SMALL MOLECULE ALPHA4BETA7 INTEGRIN INHIBITORFiled as ELI LILLY AND COMPANY2026-01-14BRIHAD ANAND ABHYANKAR | pending |
| CRYSTALLINE FORMS OF A FARNESOID X RECEPTOR AGONISTC07D 401/14, A61P 1/16, A61P 1/00, A61P 29/00, A61K 31/4439, A61K 45/06, C07B2200/13Filed as ELI LILLY AND COMPANY2026-01-12Nicholas D. SMITH | pending |
| METHODS AND SYSTEMS FOR MONITORING ASSEMBLY LINES FOR MEDICAL DEVICESFiled as ELI LILLY AND COMPANY2026-01-02DEEPTI - | pending |
| METHODS AND SYSTEMS FOR PREDICTING CHANGES IN PHYSIOLOGICAL PARAMETERS OF A PATIENTG16H 20/10Filed as Eli Lilly and Company2025-12-17Kevin Christopher BLEICH | pending |
| NEEDLE ASSEMBLY AND FLUID DELIVERY SYSTEM WITH NEEDLE ASSEMBLYA61M 5/2466, A61M 5/31576, A61M 5/3297, A61M 5/3298, A61M2005/2474, A61M2005/31588Filed as Eli Lilly and Company2025-12-17Ho-Seon JIN | pending |
| METHODS FOR TREATING OBESITY OR AN OBESITY-RELATED DISEASE OR DISORDERFiled as ELI LILLY AND COMPANY2025-12-16DANIEL A. BRIERE | pending |
| NEUROTENSIN RECEPTOR LIGANDSA61K 51/0497, C07D 405/14, A61P 35/00, A61K 51/0453, A61K2121/00, C07D 413/14, C07D 471/04, C07D 471/10, C07D 487/08, C07D 487/10, C07D 493/04, C07F 5/003Filed as ELI LILLY AND COMPANY2025-12-16Timothy Patrick CHOLKO | pending |
| PDE3B RNA INTERFERENCE AGENTSC12N 15/1137, A61K 47/542, A61K 47/64, A61P 3/04, A61K 9/0019, A61K 31/712, A61K 31/7125, A61K 31/713, A61K 38/00, C07K 7/06, C07K 19/00, C12N2310/11, C12N2310/14, C12N2310/312, C12N2310/315, C12N2310/321, C12N2310/323, C12N2310/3513, C12N2310/3515, C12N2320/32Filed as ELI LILLY AND COMPANY2025-12-16Ricardo J. SAMMS | pending |
| NEUROTENSIN RECEPTOR LIGANDSFiled as ELI LILLY AND COMPANY2025-12-16TIMOTHY PATRICK CHOLKO | pending |
| PDE3B RNA INTERFERENCE AGENTSFiled as ELI LILLY AND COMPANY2025-12-16EITARO AIHARA | pending |
| LIPIDS HAVING A THIOGLYCEROL MOTIFFiled as ELI LILLY AND COMPANY2025-12-16JOSEPH MARTINELLI | pending |
| OPTICAL SENSING TECHNIQUES FOR DOSE DELIVERYA61M 5/3155, A61M 5/20, A61M2207/00Filed as Eli Lilly and Company2025-12-15Mark Christopher ALLEN | pending |
| METHODS OF USING RETATRUTIDEFiled as ELI LILLY AND COMPANY2025-12-15Xiaotian ZHANG | pending |
| METHODS AND SYSTEMS FOR DETECTING DEFECTS USING TOPOLOGICAL PERSISTENCE FEATURESG01N 21/8851, G06T 7/41, G01N2021/8861, G06T 7/0004, G06T2207/10024, G06T2207/20081, G06T2207/30164Filed as Eli Lilly and Company2025-12-11Yu-Min CHUNG | pending |
| THERAPEUTIC USES AND DOSES OF LP(A) DISRUPTER COMPOUNDSA61K 31/4025, A61P 9/10, A61P 9/00Filed as ELI LILLY AND COMPANY2025-12-10Shweta URVA | pending |
| TESTING TECHNIQUES FOR MEDICATION DELIVERY DEVICESFiled as ELI LILLY AND COMPANY2025-12-09JAVAD ESHRAGHI | pending |
| METHODS AND SYSTEMS FOR TRAINING AND USING A MACHINE LEARNING MODEL FOR DETECTING DEFECTSFiled as ELI LILLY AND COMPANY2025-12-03SNIGDHA AGARWAL | pending |
| OSCILLATING MIRROR ASSEMBLYFiled as ELI LILLY AND COMPANY2025-12-03EDWIN R. COMPARINI | pending |
| MEDICATION DELIVERY SYSTEMS AND METHODS INCLUDING INJECTION SITE DETERMINATION AND TRACKINGA61M 5/427, A61B 5/352, A61B 8/0875, A61M2205/3375, A61M2205/50, A61M2230/04Filed as Eli Lilly and Company2025-11-26Kelsey Christine BAYER | pending |
| METHODS AND APPARATUS FOR DETERMINING DEVICE DOSAGEG16H 20/17, A61M 5/20, G16H 40/67, G16H 50/70, G06N 20/00, A61M 5/24, A61M 5/3146, A61M 5/31535, A61M 5/31593, A61M2205/3379, A61M2205/50Filed as Eli Lilly and Company2025-11-26Jeffrey Sterling ANDREWS | pending |
| PLUNGER DRIVE SYSTEM FOR A MEDICATION DELIVERY DEVICEFiled as ELI LILLY AND COMPANY2025-11-25WINSTON SEQUEIRA | pending |
| CELLS AND COMPOSITION OF CELLS COMPRISING NUCLEIC ACID CONSTRUCTFiled as ELI LILLY AND COMPANY2025-11-25BHAVIN S. PAREKH | pending |
| ATXN2 RNA INTERFERENCE AGENTSFiled as ELI LILLY AND COMPANY2025-11-21RIAZUL ALAM | pending |
| METHODS OF CLEANING CHROMATOGRAPHY MATRICESB01D 15/203, B08B 3/08, B01D 15/3809, B01D 15/426, B01J 20/28016, B01J 20/286, B01J 20/3475, C07K 1/22, C07K 14/605, C11D 3/042, C11D 3/046, C11D 3/2079, C11D 3/30Filed as ELI LILLY AND COMPANY2025-11-21Noah TAN SHIZHAO | pending |
| AMPK-BETA-1-ACTIVATING COMPOUNDS AND METHODS OF USING THE SAMEFiled as ELI LILLY AND COMPANY2025-11-19MICHAEL GREGORY BELL | pending |
| METHODS OF USING AND COMPOSITIONS INCLUDING AN INCRETIN ANALOGA61K 38/26, A61P 3/04, A61P 3/06, A61P 3/10Filed as Eli Lilly and Company2025-11-18Tamer COSKUN | pending |
| SUBSTITUTED HETEROARYL-HETEROARYL GLUCAGON RECEPTOR AGONISTS AND THEIR USE AS THERAPIESFiled as ELI LILLY AND COMPANY2025-11-18FRANCISCO JAVIER AGEJAS CHICHARRO | pending |
| METHODS OF USING AND COMPOSITIONS INCLUDING AN INCRETIN ANALOGA61K 38/26, A61P 3/04, A61P 3/06, A61P 3/10Filed as Eli Lilly and Company2025-11-18Tamer COSKUN | pending |
| ALK7 RNA INTERFERENCE AGENTSFiled as ELI LILLY AND COMPANY2025-11-17EITARO AIHARA | pending |
| PLIN1 RNAi INTERFERENCE AGENTSA61K 47/64, C12N 15/1138, A61P 3/04, C12N2310/14, C12N2310/313, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/333, C12N2310/335, C12N2310/336, C12N2310/351, C12N2310/3513, C12N2310/3515, C12N2310/3521, C12N2310/3535Filed as ELI LILLY AND COMPANY2025-11-17James Warren PERFIELD II | pending |
| PLIN1 RNA INTERFERENCE AGENTSFiled as ELI LILLY AND COMPANY2025-11-17EITARO AIHARA | pending |
| PDE3B RNA INTERFERENCE AGENTSFiled as ELI LILLY AND COMPANY2025-11-14Ricardo J. SAMMS | pending |
| ORAL COMPOSITIONS COMPRISING LP(A) INHIBITOR COMPOUNDSFiled as ELI LILLY AND COMPANY2025-11-13SYDNEY MARIE BUTIKOFER | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on LLY
Company overviewEverything on LLY in one place, with the price.SEC filingsWhat LLY's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat LLY's own officers and directors buy and sell.Planned salesSales LLY insiders have filed notice of.Who owns itEvery manager reporting a position in LLY.Funds holding itWhich funds and ETFs hold LLY, and how big a bet.LobbyingWhat LLY spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on LLY's account, and who they worked for.Federal contractsWhat federal agencies pay LLY.Workplace safetyWhat OSHA found at LLY's sites.